Using organoid models to predict chemotherapy efficacy: the future of precision oncology?

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Arruebo M, Vilaboa N, Saez-Gutierrez B, et al. Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 2011 Aug 12;3(3):3279–3330.
   PubMedGoogle Scholar
• Baynam G, Bowman F, Lister K. Improved diagnosis and care for rare diseases through implementation of precision public health framework. In: Posada de la PM, Taruscio D, Groft SC, et al. editors. Rare diseases epidemiology: update and overview. Cham:Springer International Publishing; 2017. p. 55–94.
   Google Scholar
• Bertier G, Carrot-Zhang J, Ragoussis V, et al. Integrating precision cancer medicine into healthcare-policy, practice, and research challenges. Genome Med. 2016 Oct 24;8(1):108.
   PubMedGoogle Scholar
• Hall MJ, Obeid EI, Schwartz SC, et al. Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond. Gynecol Oncol. 2016 Mar;140(3):565–574.
   PubMed Web of Science ®Google Scholar
• Madhavan S, Subramaniam S, Brown TD, et al. Art and challenges of precision medicine: interpreting and integrating genomic data into clinical practice. Am Soc Clin Oncol Educ Book. 2018;38:546–553.
   PubMedGoogle Scholar
• Palumbo MO, Kavan P, Miller WH Jr., et al. Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol. 2013;4:57.
   PubMed Web of Science ®Google Scholar
• Tran G, Zafar SY. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med. 2018 May;6(9):166.
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences E, and Medicine. Applying an implementation science approach to genomic medicine: workshop summary. Washington, DC: The National Academies Press. 2016; 2016.
   Google Scholar
• Rossi G, Manfrin A, Lutolf MP. Progress and potential in organoid research. Nat Rev Genet. 2018 Nov;19(11):671–687.
   PubMed Web of Science ®Google Scholar
• Petersen OW, Ronnov-Jessen L, Howlett AR, et al. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9064–9068.
   PubMed Web of Science ®Google Scholar
• Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009 May 14;459(7244):262–265.
   PubMed Web of Science ®Google Scholar
• Eiraku M, Takata N, Ishibashi H, et al. Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature. 2011 Apr 7;472(7341):51–56.
   PubMed Web of Science ®Google Scholar
• Simian M, Bissell MJ. Organoids: A historical perspective of thinking in three dimensions. J Cell Biol. 2017 Jan 2;216(1):31–40.
   PubMed Web of Science ®Google Scholar
• Sugaya M, Takenoyama M, Osaki T, et al. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest. 2002 Jul;122(1):282–288.
   PubMed Web of Science ®Google Scholar
• Lin W, Yip YL, Jia L, et al. Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma. Nat Commun. 2018 Nov 7;9(1):4663.
   PubMedGoogle Scholar
• Dangles-Marie V, Pocard M, Richon S, et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res. 2007 Jan 1;67(1):398–407.
   PubMed Web of Science ®Google Scholar
• Weeber F, Ooft SN, Dijkstra KK, et al. Tumor organoids as a pre-clinical cancer model for drug discovery. Cell Chem Biol. 2017 Sep 21;24(9):1092–1100.
   PubMed Web of Science ®Google Scholar
• van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015 May 7;161(4):933–945.
   PubMed Web of Science ®Google Scholar
• Weeber F, van de Wetering M, Hoogstraat M, et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13308–13311.
   PubMed Web of Science ®Google Scholar
• Huang L, Holtzinger A, Jagan I, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med. 2015 Nov;21(11):1364–1371.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao J, Zhang L, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8(5):761–773.
   PubMed Web of Science ®Google Scholar
• Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012 Dec 1;125(Pt 23):5591–5596.
   PubMed Web of Science ®Google Scholar
• Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst. 2013 Apr 3;105(7):452–458.
   PubMedGoogle Scholar
• Batchelder CA, Martinez ML, Duru N, et al. Three dimensional culture of human renal cell carcinoma organoids. PLoS One. 2015;10(8):e0136758.
   PubMed Web of Science ®Google Scholar
• Nadauld LD, Garcia S, Natsoulis G, et al. Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. Genome Biol. 2014 Aug 27;15(8):428.
   PubMed Web of Science ®Google Scholar
• Li X, Nadauld L, Ootani A, et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med. 2014 Jul;20(7):769–777.
   PubMed Web of Science ®Google Scholar
• Matano M, Date S, Shimokawa M, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med. 2015 Mar;21(3):256–262.
   PubMed Web of Science ®Google Scholar
• Skardal A, Devarasetty M, Rodman C, et al. Liver-tumor hybrid organoids for modeling tumor growth and drug response in vitro. Ann Biomed Eng. 2015 Oct;43(10):2361–2373.
   PubMed Web of Science ®Google Scholar
• Skardal A, Devarasetty M, Forsythe S, et al. A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening. Biotechnol Bioeng. 2016 Sep;113(9):2020–2032.
   PubMed Web of Science ®Google Scholar
• Zanoni M, Piccinini F, Arienti C, et al. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Sci Rep. 2016 Jan 11;6:19103.
   PubMed Web of Science ®Google Scholar
• Costa EC, Moreira AF, de Melo-Diogo D, et al. 3D tumor spheroids: an overview on the tools and techniques used for their analysis. Biotechnol Adv. 2016 Dec;34(8):1427–1441.
   PubMed Web of Science ®Google Scholar
• Lu P, Takai K, Weaver VM, et al. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 2011 Dec 1;3(12):a005058.
   PubMed Web of Science ®Google Scholar
• Tibbitt MW, Anseth KS. Hydrogels as extracellular matrix mimics for 3D cell culture. Biotechnol Bioeng. 2009 Jul 1;103(4):655–663.
   PubMed Web of Science ®Google Scholar
• Aleman J, Skardal A. A multi-site metastasis-on-a-chip microphysiological system for assessing metastatic preference of cancer cells. Biotechnol Bioeng. 2019 Apr;116(4):936–944.
   PubMed Web of Science ®Google Scholar
• Hastings JF, Skhinas JN, Fey D, et al. The extracellular matrix as a key regulator of intracellular signalling networks. Br J Pharmacol. 2019 Jan;176(1):82–92.
   PubMed Web of Science ®Google Scholar
• Skhinas JN, Cox TR. The interplay between extracellular matrix remodelling and kinase signalling in cancer progression and metastasis. Cell Adh Migr. 2018;12(6):529–537.
   PubMed Web of Science ®Google Scholar
• Boussommier-Calleja A, Atiyas Y, Haase K, et al. The effects of monocytes on tumor cell extravasation in a 3D vascularized microfluidic model. Biomaterials. 2019;198:180–193.
   PubMed Web of Science ®Google Scholar
• Moore N, Doty D, Zielstorff M, et al. A multiplexed microfluidic system for evaluation of dynamics of immune-tumor interactions. Lab Chip. 2018 Jun 26;18(13):1844–1858.
   PubMed Web of Science ®Google Scholar
• Jeon JS, Bersini S, Gilardi M, et al. Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation. Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):214–219.
   PubMed Web of Science ®Google Scholar
• Caballero D, Kaushik S, Correlo VM, et al. Organ-on-chip models of cancer metastasis for future personalized medicine: from chip to the patient. Biomaterials. 2017;149:98–115.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Shiratsuchi H, Palanisamy N, et al. Expanded circulating tumor cells from a patient with ALK-positive lung cancer present with EML4-ALK rearrangement along with resistance mutation and enable drug sensitivity testing: A case study. J Thorac Oncol. 2017 Feb;12(2):397–402.
   PubMed Web of Science ®Google Scholar
• Praharaj PP, Bhutia SK, Nagrath S, et al. Circulating tumor cell-derived organoids: current challenges and promises in medical research and precision medicine. Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):117–127.
   PubMed Web of Science ®Google Scholar
• Cantrell MA, Kuo CJ. Organoid modeling for cancer precision medicine. Genome Med. 2015;7(1):32.
   PubMedGoogle Scholar
• Nagle PW, Plukker JTM, Muijs CT, et al. Patient-derived tumor organoids for prediction of cancer treatment response. Semin Cancer Biol. 2018;53:258–264.
   PubMed Web of Science ®Google Scholar
• Hubert CG, Rivera M, Spangler LC, et al. A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. Cancer Res. 2016 Apr 15;76(8):2465–2477.
   PubMed Web of Science ®Google Scholar
• Fong EL, Wan X, Yang J, et al. A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials. 2016;77:164–172.
   PubMed Web of Science ®Google Scholar
• Belloni D, Heltai S, Ponzoni M, et al. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment. Haematologica. 2018 Apr;103(4):707–716.
   PubMed Web of Science ®Google Scholar
• Braham MVJ, Minnema MC, Aarts T, et al. Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model. Oncoimmunology. 2018;7(6):e1434465.
   PubMed Web of Science ®Google Scholar
• Ferrarini M, Steimberg N, Ponzoni M, et al. Ex-vivo dynamic 3-D culture of human tissues in the RCCS bioreactor allows the study of multiple myeloma biology and response to therapy. PLoS One. 2013;8(8):e71613.
   PubMed Web of Science ®Google Scholar
• Beshiri ML, Tice CM, Tran C, et al. A PDX/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening. Clin Cancer Res. 2018 Sep 1;24(17):4332–4345.
   PubMed Web of Science ®Google Scholar
• Shenoy TR, Boysen G, Wang MY, et al. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. Ann Oncol. 2017 Jul 1;28(7):1495–1507.
   PubMed Web of Science ®Google Scholar
• Gheibi P, Zeng S, Son KJ, et al. Microchamber Cultures Of Bladder Cancer: A platform for characterizing drug responsiveness and resistance in PDX and primary cancer cells. Sci Rep. 2017 Sep 25;7(1):12277.
   PubMedGoogle Scholar
• Schnalzger TE, de Groot MH, Zhang C, et al. 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids. Embo J. 2019 Jun 17;38(12):2100928.
   PubMed Web of Science ®Google Scholar
• Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology. 2011 Nov;141(5):1762–1772.
   PubMed Web of Science ®Google Scholar
• Aberle MR, Burkhart RA, Tiriac H, et al. Patient-derived organoid models help define personalized management of gastrointestinal cancer. Br J Surg. 2018 Jan;105(2):e48–e60.
   PubMed Web of Science ®Google Scholar
• Nanki K, Toshimitsu K, Takano A, et al. Divergent Routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis. Cell. 2018 Aug 9;174(4):856–869 e17.
   PubMed Web of Science ®Google Scholar
• Steele NG, Chakrabarti J, Wang J, et al. An organoid-based preclinical model of human gastric cancer. Cell Mol Gastroenterol Hepatol. 2019;7(1):161–184.
   PubMed Web of Science ®Google Scholar
• Gao M, Lin M, Rao M, et al. Development of patient-derived gastric cancer organoids from endoscopic biopsies and surgical tissues. Ann Surg Oncol. 2018 Sep;25(9):2767–2775.
   PubMed Web of Science ®Google Scholar
• Yan HHN, Siu HC, Law S, et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell. 2018 Dec 6;23(6):882–897.e11.
   PubMed Web of Science ®Google Scholar
• Seidlitz T, Merker SR, Rothe A, et al. Human gastric cancer modelling using organoids. Gut. 2019 Feb;68(2):207–217.
   PubMed Web of Science ®Google Scholar
• Kondo J, Endo H, Okuyama H, et al. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6235–6240.
   PubMed Web of Science ®Google Scholar
• Ashley N, Jones M, Ouaret D, et al. Rapidly derived colorectal cancer cultures recapitulate parental cancer characteristics and enable personalized therapeutic assays. J Pathol. 2014 Sep;234(1):34–45.
   PubMed Web of Science ®Google Scholar
• Verissimo CS, Overmeer RM, Ponsioen B, et al. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. Elife. 2016 Nov15;5:e18489.
   Google Scholar
• Usui T, Sakurai M, Enjoji S, et al. Establishment of a novel model for anticancer drug resistance in three-dimensional primary culture of tumor microenvironment. Stem Cells Int. 2016;2016:7053872.
   PubMedGoogle Scholar
• Usui T, Sakurai M, Umata K, et al. Hedgehog signals mediate anti-cancer drug resistance in three-dimensional primary colorectal cancer organoid culture. Int J Mol Sci. 2018 Apr 6;19(4):1098.
   Web of Science ®Google Scholar
• Schutte M, Risch T, Abdavi-Azar N, et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun. 2017 Feb 10;8:14262.
   PubMed Web of Science ®Google Scholar
• Tashiro T, Okuyama H, Endo H, et al. In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer. PLoS One. 2017 Mar 16;12(3):e0174151.
   PubMed Web of Science ®Google Scholar
• Jeppesen M, Hagel G, Glenthoj A, et al. Short-term spheroid culture of primary colorectal cancer cells as an in vitro model for personalizing cancer medicine. PLoS One. 2017;12(9):e0183074.
   PubMed Web of Science ®Google Scholar
• Buzzelli JN, Ouaret D, Brown G, et al. Colorectal cancer liver metastases organoids retain characteristics of original tumor and acquire chemotherapy resistance. Stem Cell Res. 2018;27:109–120.
   PubMed Web of Science ®Google Scholar
• Zhao H, Yan C, Hu Y, et al. Sphereforming assay vs. organoid culture: determining longterm stemness and the chemoresistant capacity of primary colorectal cancer cells. Int J Oncol. 2019 Mar;54(3):893–904.
   PubMed Web of Science ®Google Scholar
• Schumacher D, Andrieux G, Boehnke K, et al. Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures. PLoS Genet. 2019 Mar 29;15(3):e1008076.
   PubMed Web of Science ®Google Scholar
• Forsythe S, Mehta N, Devarasetty M, et al. Development of a colorectal cancer 3D micro-tumor construct platform from cell lines and patient tumor biospecimens for standard-of-care and experimental drug screening. Ann Biomed Eng. 2019 April 24.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Endo H, Okami J, Okuyama H, et al. Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation. J Thorac Oncol. 2013 Feb;8(2):131–139.
   PubMed Web of Science ®Google Scholar
• Ruppen J, Wildhaber FD, Strub C, et al. Towards personalized medicine: chemosensitivity assays of patient lung cancer cell spheroids in a perfused microfluidic platform. Lab Chip. 2015 Jul 21;15(14):3076–3085.
   PubMed Web of Science ®Google Scholar
• Mazzocchi AR, Rajan SAP, Votanopoulos KI, et al. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening. Sci Rep. 2018 Feb 13;8(1):2886.
   PubMedGoogle Scholar
• Zhang Z, Wang H, Ding Q, et al. Establishment of patient-derived tumor spheroids for non-small cell lung cancer. PLoS One. 2018;13(3):e0194016.
   PubMed Web of Science ®Google Scholar
• Mazzocchi A, Devarasetty M, Herberg S, et al. Pleural effusion aspirate for use in 3D lung cancer modeling and chemotherapy screening. ACS Biomater Sci Eng. 2019 March 8;5(4):1937–1943.
   PubMed Web of Science ®Google Scholar
• Breslin S, O’Driscoll L. The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance. Oncotarget. 2016 Jul 19;7(29):45745–45756.
   PubMedGoogle Scholar
• Walsh AJ, Cook RS, Sanders ME, et al. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res. 2014 Sep 15;74(18):5184–5194.
   PubMed Web of Science ®Google Scholar
• Walsh AJ, Cook RS, Sanders ME, et al. Drug response in organoids generated from frozen primary tumor tissues. Sci Rep. 2016 Jan;7(6):18889.
   Google Scholar
• Shirure VS, Bi Y, Curtis MB, et al. Tumor-on-a-chip platform to investigate progression and drug sensitivity in cell lines and patient-derived organoids. Lab Chip. 2018 Dec 7;18(23):3687–3702.
   PubMed Web of Science ®Google Scholar
• Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018 Jan 11;172(1–2):373–386.e10.
   PubMed Web of Science ®Google Scholar
• Al Bandar MH, Kim NK. Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review). Oncol Rep. 2017 May;37(5):2553–2564.
   PubMed Web of Science ®Google Scholar
• Uggeri F, Ronchi PA, Goffredo P, et al. Metastatic liver disease from non-colorectal, non-neuroendocrine, non-sarcoma cancers: a systematic review. World J Surg Oncol. 2015 May;29(13):191.
   Google Scholar
• Broutier L, Mastrogiovanni G, Verstegen MM, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017 Dec;23(12):1424–1435.
   PubMed Web of Science ®Google Scholar
• Nuciforo S, Fofana I, Matter MS, et al. Organoid models of human liver cancers derived from tumor needle biopsies. Cell Rep. 2018 Jul 31;24(5):1363–1376.
   PubMed Web of Science ®Google Scholar
• Li L, Knutsdottir H, Hui K, et al. Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. JCI Insight. 2019 Jan 24;4(2):121490.
   Web of Science ®Google Scholar
• McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018 Nov 21;24(43):4846–4861.
   PubMed Web of Science ®Google Scholar
• Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015 Jan 15;160(1–2):324–338.
   PubMed Web of Science ®Google Scholar
• Seino T, Kawasaki S, Shimokawa M, et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. Cell Stem Cell. 2018 Mar 1;22(3):454–467 e6.
   PubMed Web of Science ®Google Scholar
• Tsai S, McOlash L, Palen K, et al. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer. 2018 Mar 27;18(1):335.
   PubMedGoogle Scholar
• Romero-Calvo I, Weber CR, Ray M, et al. Human organoids share structural and genetic features with primary pancreatic adenocarcinoma tumors. Mol Cancer Res. 2019 Jan;17(1):70–83.
   PubMed Web of Science ®Google Scholar
• Tiriac H, Belleau P, Engle DD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018 Sep;8(9):1112–1129.
   PubMed Web of Science ®Google Scholar
• Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017 Feb;14(1):9–32.
   PubMed Web of Science ®Google Scholar
• Jabs J, Zickgraf FM, Park J, et al. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations. Mol Syst Biol. 2017 Nov 27;13(11):955.
   PubMed Web of Science ®Google Scholar
• Hill SJ, Decker B, Roberts EA, et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov. 2018 Nov;8(11):1404–1421.
   PubMed Web of Science ®Google Scholar
• Phan N, Hong JJ, Tofig B, et al. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids. Commun Biol. 2019 Feb;2:78.
   PubMed Web of Science ®Google Scholar
• Kopper O, de Witte CJ, Lohmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019 May;25(5):838–849.
   PubMed Web of Science ®Google Scholar
• Turco MY, Gardner L, Hughes J, et al. Long-term, hormone-responsive organoid cultures of human endometrium in a chemically defined medium. Nat Cell Biol. 2017 May;19(5):568–577.
   PubMed Web of Science ®Google Scholar
• Villa PL, Jackson R, Eade S, et al. Isolation of biopsy-derived, human cervical keratinocytes propagated as monolayer and organoid cultures. Sci Rep. 2018 Dec 14;8(1):17869.
   PubMedGoogle Scholar
• Van Nyen T, Moiola CP, Colas E, et al. Modeling endometrial cancer: past, present, and future. Int J Mol Sci. 2018 Aug 9;19(8):E2348.
   Web of Science ®Google Scholar
• Kiyohara Y, Yoshino K, Kubota S, et al. Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer. Cancer Sci. 2016 Apr;107(4):452–460.
   PubMed Web of Science ®Google Scholar
• Girda E, Huang EC, Leiserowitz GS, et al. The use of endometrial cancer patient-derived organoid culture for drug sensitivity testing is feasible. Int J Gynecol Cancer. 2017 Oct;27(8):1701–1707.
   PubMed Web of Science ®Google Scholar
• Tamura H, Higa A, Hoshi H, et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. Oncol Rep. 2018 Aug;40(2):635–646.
   PubMed Web of Science ®Google Scholar
• Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol. 2012;4:1–11.
   PubMedGoogle Scholar
• Wang S, Gao D, Chen Y. The potential of organoids in urological cancer research. Nat Rev Urol. 2017 Jul;14(7):401–414.
   PubMed Web of Science ®Google Scholar
• Drost J, Karthaus WR, Gao D, et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat Protoc. 2016 Feb;11(2):347–358.
   PubMed Web of Science ®Google Scholar
• Namekawa T, Ikeda K, Horie-Inoue K, et al. Application of prostate cancer models for preclinical study: advantages and limitations of cell lines, patient-derived xenografts, and three-dimensional culture of patient-derived cells. Cells. 2019 Jan 20;8(1):74.
   PubMed Web of Science ®Google Scholar
• Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014 Sep 25;159(1):176–187.
   PubMed Web of Science ®Google Scholar
• Puca L, Bareja R, Prandi D, et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun. 2018 Jun 19;9(1):2404.
   PubMedGoogle Scholar
• Linxweiler J, Hammer M, Muhs S, et al. Patient-derived, three-dimensional spheroid cultures provide a versatile translational model for the study of organ-confined prostate cancer. J Cancer Res Clin Oncol. 2019 Mar;145(3):551–559.
   PubMed Web of Science ®Google Scholar
• Lobo NC, Gedye C, Apostoli AJ, et al. Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicine. BMC Cancer. 2016 Jul;16(16):485.
   PubMedGoogle Scholar
• Okuyama H, Yoshida T, Endo H, et al. Involvement of heregulin/HER3 in the primary culture of human urothelial cancer. J Urol. 2013 Jul;190(1):302–310.
   PubMed Web of Science ®Google Scholar
• Burgues JP, Gomez L, Pontones JL, et al. A chemosensitivity test for superficial bladder cancer based on three-dimensional culture of tumour spheroids. Eur Urol. 2007 Apr;51(4):962–969; discussion 969–970.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Okuyama H, Nakayama M, et al. High-dose chemotherapeutics of intravesical chemotherapy rapidly induce mitochondrial dysfunction in bladder cancer-derived spheroids. Cancer Sci. 2015 Jan;106(1):69–77.
   PubMed Web of Science ®Google Scholar
• Lee SH, Hu W, Matulay JT, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 2018 Apr 5;173(2):515–528.e17.
   PubMed Web of Science ®Google Scholar
• Miller CP, Tsuchida C, Zheng Y, et al. A 3D human renal cell carcinoma-on-a-chip for the study of tumor angiogenesis. Neoplasia. 2018 Jun;20(6):610–620.
   PubMed Web of Science ®Google Scholar
• Grassi L, Alfonsi R, Francescangeli F, et al. Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases. Cell Death Dis. 2019 Feb 27;10(3):201.
   PubMedGoogle Scholar
• Mullenders J, de Jongh E, Brousali A, et al. Mouse and human urothelial cancer organoids: A tool for bladder cancer research. Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4567–4574.
   PubMed Web of Science ®Google Scholar
• Pauli C, Hopkins BD, Prandi D, et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 2017 May;7(5):462–477.
   PubMed Web of Science ®Google Scholar
• Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018 Feb 23;359(6378):920–926.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Osman AA, Takahashi Y, et al. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity. Oral Oncol. 2018;87:49–57.
   PubMed Web of Science ®Google Scholar
• Saengwimol D, Rojanaporn D, Chaitankar V, et al. A three-dimensional organoid model recapitulates tumorigenic aspects and drug responses of advanced human retinoblastoma. Sci Rep. 2018 Oct 23;8(1):15664.
   PubMedGoogle Scholar
• Kijima T, Nakagawa H, Shimonosono M, et al. Three-dimensional organoids reveal therapy resistance of esophageal and oropharyngeal squamous cell carcinoma cells. Cell Mol Gastroenterol Hepatol. 2018 Sep 14;7(1):73–91.
   Google Scholar
• Votanopoulos KI, Mazzocchi A, Sivakumar H, et al. Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study. Ann Surg Oncol. 2019 Jan;26(1):139–147.
   PubMed Web of Science ®Google Scholar
• Linkous A, Balamatsias D, Snuderl M, et al. Modeling patient-derived glioblastoma with cerebral organoids. Cell Rep. 2019 Mar 19;26(12):3203–3211.e5.
   PubMed Web of Science ®Google Scholar
• Saito Y, Muramatsu T, Kanai Y, et al. Establishment of patient-derived organoids and drug screening for biliary tract carcinoma. Cell Rep. 2019 Apr 23;27(4):1265–1276.e4.
   PubMed Web of Science ®Google Scholar
• Dijkstra KK, Cattaneo CM, Weeber F, et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell. 2018 Sep 6;174(6):1586–1598.e12.
   PubMed Web of Science ®Google Scholar
• Neal JT, Li X, Zhu J, et al. Organoid modeling of the tumor immune microenvironment. Cell. 2018 Dec 13;175(7):1972–1988.e16.
   PubMed Web of Science ®Google Scholar
• Courau T, Bonnereau J, Chicoteau J, et al. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment. J Immunother Cancer. 2019 Mar 14;7(1):74.
   PubMedGoogle Scholar
• Castell JV, Gomez-Lechon MJ. Liver cell culture techniques. Methods Mol Biol. 2009;481:35–46.
   PubMedGoogle Scholar
• Mitra A, Mishra L, Li S. Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol. 2013 Jun;31(6):347–354.
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Kurvari V, Virmani A, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer. 1998 Dec 9;78(6):766–774.
   PubMed Web of Science ®Google Scholar
• Elbadawy M, Usui T, Yamawaki H, et al. Development of an experimental model for analyzing drug resistance in colorectal cancer. Cancers (Basel). 2018 May 28;10(6):E164.
   PubMed Web of Science ®Google Scholar
• Organoid Based Response Prediction in Esophageal Cancer. [cited 2019 Jun 6]. Available from: https://ClinicalTrials.gov/show/NCT03283527
   Google Scholar
• Patient-derived organoid model and circulating tumor cells for treatment response of lung cancer.  [cited 2019 Jun 6]. Available from: https://ClinicalTrials.gov/show/NCT03655015
   Google Scholar
• Clinical study on drug sensitivity verification or prediction of therapy for breast cancer by patient-derived organoid model.  [cited 2019 Jun 6]. Available from: https://ClinicalTrials.gov/show/NCT03544047
   Google Scholar
• Establishing organoids from metastatic pancreatic cancer patients, the OPT-I study. [cited 2019 May 28]. Available from: https://ClinicalTrials.gov/show/NCT03500068
   Google Scholar
• Pancreatic cancer models developed from EUS guided biopsy tissue. [cited 2019 May 28]. Available from: https://ClinicalTrials.gov/show/NCT03140592
   Google Scholar